IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.

Di Loreto C, Celleno R, Piastrella L, Del Sindaco P

European review for medical and pharmacological sciences1 Oct 2020Cited by 11 (Europe PMC)

PMID33155225DOI10.26355/eurrev_202010_23425PepBankPUB-33155225

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In real-world adults with type 2 diabetes, the fixed-ratio combination IDegLira (insulin degludec plus liraglutide) was effective in reducing HbA1c, especially in the GLP-1 RA and BOT subgroups.
In plain wordsIn real-world adults with type 2 diabetes, the insulin and liraglutide combination IDegLira lowered HbA1c, mainly in two subgroups.
Peptide
Liraglutide
Outcome
DecreaseHbA1c with IDegLira
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
IDegLira results to be effective in reducing HbA1c and fasting plasma glucose
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted in the Diabetology Service of the Umbria local sanitary agency (USL Umbria 1) in Perugia.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3315522501
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In real-world adults with type 2 diabetes, the fixed-ratio combination IDegLira (insulin degludec plus liraglutide) was effective in reducing fasting plasma glucose, especially in the GLP-1 RA and BOT subgroups.
In plain wordsIn real-world adults with type 2 diabetes, the insulin and liraglutide combination IDegLira lowered fasting blood sugar, mainly in two subgroups.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose with IDegLira
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
IDegLira results to be effective in reducing HbA1c and fasting plasma glucose, especially among GLP-1 RA and BOT subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted in the Diabetology Service of the Umbria local sanitary agency (USL Umbria 1) in Perugia.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3315522502
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In real-world adults with type 2 diabetes on basal insulin, the fixed-ratio combination IDegLira showed a statistical difference from the first month of treatment, also for post-prandial glycemia.
In plain wordsIn real-world adults with type 2 diabetes on basal insulin, the insulin and liraglutide combination changed blood sugar after meals from the first month.
Peptide
Liraglutide
Outcome
Direction not reportedPost-prandial glycemia with IDegLira in the BOT group
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In BOT group, a statistical difference was noted from the first month of treatment, also for post-prandial glycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted in the Diabetology Service of the Umbria local sanitary agency (USL Umbria 1) in Perugia.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3315522503
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In real-world adults with type 2 diabetes in the BB group, the fixed-ratio combination IDegLira allowed a significant reduction of the amount of basal insulin.
In plain wordsIn real-world adults with type 2 diabetes, switching to the insulin and liraglutide combination IDegLira meant a lower basal insulin dose.
Peptide
Liraglutide
Outcome
DecreaseBasal insulin dose reduction with IDegLira in BB patients
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Obtained results were achieved at a moderate dose of IDegLira reported during the study, which also represents a significant reduction of the amount of basal insulin in BB patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted in the Diabetology Service of the Umbria local sanitary agency (USL Umbria 1) in Perugia.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3315522504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.